Solid Biosciences: Positive FDA Meeting For SGT-003 Sets Up Next Milestones
2026-02-09 18:22:31 ET
The last time I spoke about Solid Biosciences Inc. ( SLDB ), it was with respect to a Seeking Alpha article entitled " Solid Biosciences: Differentiating Factors Of SGT-212 To Set Itself Apart ". With respect to this article, I mentioned that this biotech was in the process of gearing up to initiate a phase 1b study of gene therapy SGT-212 for the treatment of patients with Friedreich's Ataxia ((FA)). I'm happy to state as an update that the first patient had already been dosed in the phase 1b FALCON trial using SGT-212 for the treatment of these FA patients. On top of that, the company expects to be able to release initial data from this FALCON trial in the 2nd half of 2026....
Read the full article on Seeking Alpha
For further details see:
Solid Biosciences: Positive FDA Meeting For SGT-003 Sets Up Next Milestones
NASDAQ: SLDB
SLDB Trading
3.01% G/L:
$5.82 Last:
2,001,039 Volume:
$6.25 Open:
